Early clinical trials studying single agent Immunotherapy with Pembrolizumab and Atezolizumab for mTNBC showed long-lasting responses in some patients and notably in 1st line of treatment.
In Nov.2020 based on results Keynote 355 study, FDA granted accelerated approval to Pembrolizumab in combination with chemotherapy for patients with mTNBC whose tumors expressed PDL1(CPS>10) as determined by FDA approved rest.
In August 2021, initial approval of Atezolizumab with nab -Paclitaxel in mTNBC was withdrawn as continued approval was dependent on IMpassion -131 clinical trial meeting PFS as an end point.
Immunotherapy for mTNBC has brought significant improvement in treatment outcomes for PDL1 positive patients.
Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
